The COVID-19 pandemic has triggered intense and widespread action among the biopharma industry and its regulators. As organizations move to accelerate interventions to treat and prevent COVID-19, understanding the impact on patient populations and subpopulations is critical.

This need comes as the clinical trial infrastructure is disrupted—nearly two-thirds of 170 clinical trial sites surveyed in the U.S. believe patients will be less likely to enroll in new clinical research trials due to COVID-19—and biopharma may need to turn to non-traditional trials to help answer questions on the safety and effectiveness of treatments.

With so much at stake, we must act quickly to assess and advance treatments for COVID-19, yet no less rigorously in upholding evidence standards. Manufacturers and regulators need reliable, replicable, and transparent evidence now more than ever.

That is why HealthVerity and Aetion have launched Real-Time Insights and Evidence, the first and only real-world evidence system that combines COVID-ready analytics with near real-time data, to assess treatment approaches for COVID-19. 

Real-world evidence can and must play an important role in addressing these high-stakes questions in the current climate. We’ve amassed data that cut across care settings and that are simultaneously current and complete, along with regulatory-grade analytic capabilities to help manufacturers and regulators quickly reach valid answers. 

HealthVerity and Aetion created this offering to meet this challenge: to support in-the-moment and adaptive response as data accrue, to enable decision-ready evidence, and to ensure transparency around its generation—to determine which treatments work best, for whom, and when.

COVID-19 is an unprecedented shock to the health care system. Joined together and with our biopharma partners, we’re ready for the hard work ahead.